Evidence map›Paper›PMID 38507720›Full record

ArticleCancer research2024

A Subpopulation of Luminal Progenitors Secretes Pleiotrophin to Promote Angiogenesis and Metastasis in Inflammatory Breast Cancer.

Mengmeng Zhang, Kaiwen Zhou, Zilin Wang, Ting Liu, Laura E Stevens, Filipa Lynce, Wendy Y Chen, Sui Peng, Yubin Xie, Duanyang Zhai and 10 more

Abstract read
In one paragraph

Article in Cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. World journal of gastroenterology · 2026
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Neuropilin-1: A Multifaceted Target for Cancer Therapy.Current oncology (Toronto, Ont.) · 2025
    Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Mengmeng Zhang *Breast Disease Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.ORCID 0009-0002-8467-7838
Kaiwen Zhou *Breast Disease Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.ORCID 0000-0001-9804-2783
Zilin Wang *Breast Disease Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.ORCID 0000-0002-8748-7768
Ting Liu *Breast Disease Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.ORCID 0009-0003-1525-5962
Laura E StevensDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-6692-4009
Filipa LynceDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0001-6615-7076
Wendy Y ChenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-6946-1206
Sui PengInstitute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.ORCID 0000-0002-7399-2579
Yubin XieInstitute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.ORCID 0000-0002-3566-4849
Duanyang ZhaiBreast Disease Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.ORCID 0000-0002-2613-1397
Qianjun ChenDepartment of Breast Oncology, Traditional Chinese Medicine Hospital of Guangdong Province, Guangzhou, Guangdong, China.ORCID 0000-0001-6761-7740
Yawei ShiBreast Disease Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.ORCID 0000-0002-2602-5383
Huijuan ShiDepartment of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.ORCID 0009-0003-2738-8906
Zhongyu YuanDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.ORCID 0000-0002-2920-9671
Xiaoping LiDepartment of Breast Oncology, Jiangmen Central Hospital, Jiangmen, China.ORCID 0000-0002-0603-0820
Juan XuDepartment of Breast Oncology, Maternal and Child Health Care Hospital of Guangdong Province, Guangzhou, China.ORCID 0009-0003-3022-9500
Zhenhai CaiDepartment of Breast Oncology, Jieyang People's Hospital, Jieyang, China.ORCID 0009-0009-5422-7773
Jianping GuoInstitute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.ORCID 0000-0002-8158-0101
Nan ShaoBreast Disease Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.ORCID 0000-0002-2317-2193
Ying LinBreast Disease Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.ORCID 0000-0002-5923-3306

Funding

Beijing Science and Technology Innovation Medical Development Foundation KC2021-JX-0044-11National Key Research and Development Program of China (NKPs) 2021YFE0206300National Natural Science Foundation of China (NSFC) 82372781
6 · The paper itself

Abstract

Inflammatory breast cancer (IBC) is a highly aggressive subtype of breast cancer characterized by rapidly arising diffuse erythema and edema. Genomic studies have not identified consistent alterations and mechanisms that differentiate IBC from non-IBC tumors, suggesting that the microenvironment could be a potential driver of IBC phenotypes. Here, using single-cell RNA sequencing, multiplex staining, and serum analysis in patients with IBC, we identified enrichment of a subgroup of luminal progenitor (LP) cells containing high expression of the neurotropic cytokine pleiotrophin (PTN) in IBC tumors. PTN secreted by the LP cells promoted angiogenesis by directly interacting with the NRP1 receptor on endothelial tip cells located in both IBC tumors and the affected skin. NRP1 activation in tip cells led to recruitment of immature perivascular cells in the affected skin of IBC, which are correlated with increased angiogenesis and IBC metastasis. Together, these findings reveal a role for cross-talk between LPs, endothelial tip cells, and immature perivascular cells via PTN-NRP1 axis in the pathogenesis of IBC, which could lead to improved strategies for treating IBC. SIGNIFICANCE: Nonmalignant luminal progenitor cells expressing pleiotrophin promote angiogenesis by activating NRP1 and induce a prometastatic tumor microenvironment in inflammatory breast cancer, providing potential therapeutic targets for this aggressive breast cancer subtype.

Indexed as

Carrier ProteinsCytokinesInflammatory Breast NeoplasmsNeovascularization, PathologicTumor MicroenvironmentAngiogenesisAnimalsCell Line, TumorFemaleHumansMiceNeoplasm MetastasisNeoplastic Stem CellsNeuropilin-1Carrier ProteinsCytokinesNeuropilin-1pleiotrophin

Identifiers

PMID38507720
PMCPMC11148543

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.